Sanofi, Formation Bio, and OpenAI have announced a pioneering collaboration to leverage AI in accelerating drug development. This partnership aims to revolutionize the pharmaceutical industry by combining Sanofi's proprietary data, OpenAI's advanced AI capabilities, and Formation Bio's expertise in AI-driven drug development.
Sanofi will provide critical data to build and refine AI models, aspiring to become the first biopharma company powered by AI at scale. OpenAI will contribute cutting-edge AI technology and thought leadership, while Formation Bio will offer its engineering expertise and drug pipeline. Together, they plan to enhance the drug discovery process, optimize clinical trials, and expedite the delivery of new medicines to patients.
Paul Hudson, CEO of Sanofi, emphasized that this collaboration represents a significant advancement in their AI-powered drug development journey, aiming to transform the future of pharma and expedite access to innovative treatments for patients.
Click here to read the original news story.